Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-cell and Follicular Center Lymphoma: Correlation with Clinical Outcome

ASPP2 interacts with the tumor suppressor protein p53, promotes damage-induced apoptosis, and can specifically stimulate p53 apoptotic function. Thus, ASPP2 may function as a tumor suppressor and/or play a role in the cellular response to cytotoxic injury. To explore the role of ASPP2 in human cancer, we determined ASPP2 expression in two lymphoma subtypes with differing clinical outcomes: diffuse large B-cell lymphoma (DLBCL) and follicular center lymphoma (FCL). A real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was developed to detect ASPP2 mRNA. Sixty-one DLBCL and twenty-three FCL cases were analyzed and normalized ASPP2 levels were expressed relative to an mRNA standard. We found that ASPP2 mean expression strongly correlated with lymphoma subtype: DLBCL=11.74 and FCL=4.99 (p =0.029, unpaired 2-tailed t -test). Importantly, ASPP2 expression was variable in DLBCL but not FCL (DLBCL-range, 0.04-94.6; FCL-range, 1.2-15.0). In these DLBCL cases, serum lactate dehydrogenase (LDH) was an independent predictor of survival with median survival in the high LDH group of 24 months and median survival not achieved in the normal-low LDH group (p =0.014, Log-Rank Test). Mean ASPP2 levels trended toward an inverse correlation with LDH levels: High LDH, ASPP2=6.2; Normal-low LDH, ASPP2=18.2 (p =0.074, unpaired 2-tailed t -test). In the DLBCL cases with ASPP2 levels >7.8, only 10% (1/10) had a high LDH, in contrast to cases with ASPP2 levels <7.8 in which 59% (26/44) had a high LDH (p =0.011, Fisher Exact Test). Thus, low ASPP2 mRNA levels may correlate with poor clinical outcome in lymphoma which is consistent with the hypothesis that ASPP2 may play a role in tumor formation and/or sensitivity to cytotoxic agents. Larger studies as well as analysis of different tumor types are warranted.

[1]  S. Barrans,et al.  Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.

[2]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[3]  F. Bosch,et al.  ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. , 2002, Blood.

[4]  T. Stankovic,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD / SCID mice , 2002 .

[5]  P. Multani,et al.  Non-Hodgkin's lymphoma: review of conventional treatments. , 2001, Current pharmaceutical biotechnology.

[6]  Xin Lu,et al.  ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.

[7]  R Tibshirani,et al.  Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.

[8]  L. Naumovski,et al.  p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis , 2001, Oncogene.

[9]  M. Lindström,et al.  p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53 , 2001, Oncogene.

[10]  Carl W. Miller,et al.  Analysis of the CHK2 Gene in Lymphoid Malignancies , 2001, Leukemia & lymphoma.

[11]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[12]  L. Naumovski,et al.  Proapoptotic p53-Interacting Protein 53BP2 Is Induced by UV Irradiation but Suppressed by p53 , 2000, Molecular and Cellular Biology.

[13]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[14]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[15]  R. Ueda,et al.  Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines , 2000, FEBS letters.

[16]  M. Kaminski,et al.  Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options. , 2000, Hematology. American Society of Hematology. Education Program.

[17]  Y. Nakamura,et al.  APCL, a central nervous system-specific homologue of adenomatous polyposis coli tumor suppressor, binds to p53-binding protein 2 and translocates it to the perinucleus. , 2000, Cancer research.

[18]  J. Hudson,et al.  In vivo gene expression profile analysis of human breast cancer progression. , 1999, Cancer research.

[19]  R. Siebert,et al.  Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group. , 1999, Blood.

[20]  J. Hudson,et al.  In vivo expression profile analysis of human breast cancer progression using laser microdissection, cDNA array and quantitative real-time PCR , 1999, Nature Genetics.

[21]  H. Kato,et al.  NF-κB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2 , 1999, Oncogene.

[22]  Bin Li,et al.  Stimulation of p53-mediated Transcriptional Activation by the p53-binding Proteins, 53BP1 and 53BP2* , 1998, The Journal of Biological Chemistry.

[23]  P. Koduru,et al.  Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. , 1997, Blood.

[24]  P. Hanawalt,et al.  Expression of Wild-type p53 Is Required for Efficient Global Genomic Nucleotide Excision Repair in UV-irradiated Human Fibroblasts* , 1997, The Journal of Biological Chemistry.

[25]  H. Saito,et al.  Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[26]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[27]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[28]  P. Hanawalt,et al.  Role of DNA excision repair gene defects in the etiology of cancer. , 1997, Current topics in microbiology and immunology.

[29]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[30]  J Hermans,et al.  Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Cleary,et al.  The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M , 1996, Molecular and cellular biology.

[32]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[33]  S. Elledge,et al.  Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53 , 1995, FEBS letters.

[34]  D. Ramsay,et al.  Cytogenetic evidence that a tumor suppressor gene in the long arm of chromosome 1 contributes to glioma growth. , 1995, Cancer genetics and cytogenetics.

[35]  S. Proctor,et al.  Non-Hodgkin's Lymphomas , 1994, British Journal of Cancer.

[36]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[37]  V. Reuter,et al.  Replication error-type genetic instability at 1q42-43 in human male germ cell tumors. , 1994, Cancer research.

[38]  G. Gahrton,et al.  Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions. , 1994, Blood.

[39]  L. Hartmann,et al.  Cytogenetic studies of epithelial ovarian carcinoma. , 1993, Cancer genetics and cytogenetics.

[40]  F. Mitelman,et al.  Cytogenetic findings in 33 osteosarcomas , 1993, International journal of cancer.

[41]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Barnes,et al.  The locus of the polymorphic epithelial mucin (PEM) tumour antigen on chromosome 1q21 shows a high frequency of alteration in primary human breast tumours , 1990, International journal of cancer.

[43]  I. Magrath,et al.  Non-Hodgkin's Lymphomas , 1990 .

[44]  R. Warnke,et al.  Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. , 1986, American journal of clinical pathology.

[45]  S. Rosenberg.  Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.